VBI Vaccines Inc
OTC:VBIVQ

Watchlist Manager
VBI Vaccines Inc Logo
VBI Vaccines Inc
OTC:VBIVQ
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 14.3k USD

Net Margin

-892.9%
Current
Improving
by 3 884.5%
vs 3-y average of -4 777.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-892.9%
=
Net Income
$-84m
/
Revenue
$9.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-892.9%
=
Net Income
$-84m
/
Revenue
$9.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
VBI Vaccines Inc
NASDAQ:VBIV
808.8k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 15 072 companies
7th percentile
-892.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

VBI Vaccines Inc
Glance View

Market Cap
14.3k USD
Industry
Biotechnology

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.

VBIVQ Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-892.9%
=
Net Income
$-84m
/
Revenue
$9.4m
What is VBI Vaccines Inc's current Net Margin?

The current Net Margin for VBI Vaccines Inc is -892.9%, which is above its 3-year median of -4 777.4%.

How has Net Margin changed over time?

Over the last 3 years, VBI Vaccines Inc’s Net Margin has increased from -5 906.4% to -892.9%. During this period, it reached a low of -15 947.8% on Mar 31, 2022 and a high of -892.9% on May 1, 2024.

Back to Top